AstraZeneca Withdraws Andexxa from U.S. Market

December 23, 2025

AstraZeneca will be withdrawing Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) from the U.S. Market for commercial reasons effective Dec. 22, 2025.

The decision was taken as alignment on a feasible path to convert Andexxa from conditional to traditional approval in the U.S. could not be reached. As agreed with the FDA, Andexxa will no longer be commercially sold by AstraZeneca in the U.S. after Dec. 22.

For product that has already been purchased, please contact AstraZeneca directly to discuss returnability.

For product questions or general inquiries, please contact the AstraZeneca Information Center at 1-800-236-9933. An after-hours service is available to assist with any urgent medical inquiries.

Contact Us

If you have any questions, please reach out to our friendly Wow! Customer Care team or your FFF Sales Representative. You also can reach us by calling (800) 843-7477. We're here to help!

Thank you for trusting FFF to serve your patients and communities.